1. Home
  2. RVSB vs RNTX Comparison

RVSB vs RNTX Comparison

Compare RVSB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Riverview Bancorp Inc

RVSB

Riverview Bancorp Inc

HOLD

Current Price

$5.27

Market Cap

106.9M

Sector

Finance

ML Signal

HOLD

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.87

Market Cap

89.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSB
RNTX
Founded
1923
2001
Country
United States
United States
Employees
N/A
10
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.9M
89.0M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
RVSB
RNTX
Price
$5.27
$0.87
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$7.00
$10.00
AVG Volume (30 Days)
204.6K
579.2K
Earning Date
04-28-2026
05-15-2026
Dividend Yield
1.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$53.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.74
$0.85
52 Week High
$6.22
$2.18

Technical Indicators

Market Signals
Indicator
RVSB
RNTX
Relative Strength Index (RSI) 41.09 37.92
Support Level $5.24 $0.85
Resistance Level $5.37 $1.05
Average True Range (ATR) 0.11 0.07
MACD -0.00 -0.01
Stochastic Oscillator 22.99 0.05

Price Performance

Historical Comparison
RVSB
RNTX

About RVSB Riverview Bancorp Inc

Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment services. It has single operating segment.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: